ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

Daniel Sontupe
Market Access

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs